Clinical Trials Sponsored by Eisai GmbH

Total 4089 results

Eisai Inc.

Completed

A Study in Subjects With Recurrent Malignant Glioma

Glioma

Canada, United States
Eisai Inc.

Completed

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

Parkinson Disease | Lewy Body Disease

United States, Canada
Eisai Inc.

Completed

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Ewing Sarcoma | Rhabdomyosarcoma | Refractory or Recurrent Solid Tumors | Non-Rhabdomyosarcoma Soft Tissue Sarcoma

Spain, United Kingdom, Italy, France, Germany, Greece, Poland, Switzerland
Eisai Inc.

Terminated

A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

Photosensitive Epilepsy

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Eisai Inc.

Completed

A Study of Subcutaneous Lecanemab in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan
Eisai Inc.

Completed

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Metastatic Melanoma

United States, Australia, United Kingdom, Germany
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Thyroid Cancer

United States, France, Ukraine, Peru, Russian Federation, Argentina
Eisai Inc.

Completed

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Epilepsy

United States
Eisai Inc.

Completed

A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

Insomnia

United States
Eisai Inc.

Completed

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Metastatic Breast Cancer

Poland, Ukraine, United States, Taiwan, Spain, Argentina, Bulgaria, Romania, South Africa, Australia, Canada, Singapore, Russian Federation, Brazil, Germany, Hungary, Italy, Israel, Greece, Mexico, Belgium, Czechia, France
Eisai Inc.

No longer available

An Extended Access Program for Perampanel

Partial Onset Seizures

Italy, Spain, Belgium, Israel, Poland, Taiwan, Czechia, Finland, Thailand, Malaysia, Argentina, Chile, Canada, Hungary, Australia, Lithuania, Latvia, Estonia, Netherlands, Greece, Hong Kong
Eisai Inc.

Completed

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

United States
Eisai Inc.

Completed

Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer

Metastatic Brain Cancer

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, Chile, Brazil, Canada, Mexico, Argentina
Eisai Inc.

Terminated

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Carcinoma, Hepatocellular

United States
Eisai Inc.

Completed

A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants

Dementias With Lewy Bodies

United States
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.

Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Refractory Partial Onset Seizures

United States
Eisai Inc.

Completed

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Obesity

United States
Eisai Inc.

Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Chronic Weight Management

United States
Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada
Eisai Inc.

Completed

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake (TULIP)

Obesity

United States
Eisai Inc.

Completed

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Tumors

United States
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

Mild to Moderate Diabetic Sensorimotor Polyneuropathy

United States
Eisai Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

Healthy Participants

United States
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Hepatic Impairment; Renal Impairment

United States
Eisai Inc.

Completed

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Epilepsy

Belgium, Israel, United Kingdom, Austria, Sweden, Czechia
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

United States
Eisai Inc.

Completed

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Immune Thrombocytopenia | Chronic Thrombocytopenia

Poland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia
Eisai Inc.

Completed

A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.

Advanced Solid Tumors | Lymphomas

Netherlands
Eisai Inc.

Completed

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Alzheimer's Disease

United States
Eisai Inc.

Completed

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Central Nervous System

United States
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Completed

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

Prostate Cancer

France, United States, Romania, Canada, Peru, Brazil, Russian Federation, Chile, Croatia
Eisai Inc.

Completed

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

Metabolism and Elimination

United States
Eisai Inc.

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

Crohn's Disease
Eisai Inc.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Healthy Subjects

United States
Eisai Inc.

Completed

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Healthy Subjects

United States
Eisai Inc.

Completed

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

Healthy

United States
Eisai Inc.

Completed

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Obesity

United States

3

Subscribe